Mirtazapine Instant Eg

Mirtazapine, the active ingredient in Mirtazapine Instant Eg, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral dosage form for oral use. It is prescribed for the treatment of major depressive disorder and related depressive episodes in adult patients.

GNH USA supplies Mirtazapine Instant Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine belongs to the NaSSA class and is used to manage depressive disorders.

- Major depressive disorder: reduces depressive symptoms and improves overall mood. - Depressive episodes: provides relief of depressive signs during an acute episode. - Depression with associated insomnia or loss of appetite: helps improve sleep quality and appetite, supporting recovery.

Mirtazapine may cause a range of adverse reactions, some of which are more frequent than others.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Peripheral edema

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Hepatic dysfunction - Suicidal thoughts or behavior - Severe hypotension or syncope

When prescribing or dispensing mirtazapine, several safety considerations should be observed.

- Monitor weight: patients may experience significant weight gain. - Assess for suicidal ideation: especially during early treatment or dose changes. - Caution in hepatic impairment: dose adjustment may be required. - Avoid abrupt discontinuation: taper to reduce withdrawal symptoms. - Use with caution in the elderly: increased risk of sedation and falls. - Store at room temperature: keep in the original container, protect from moisture and light.

Mirtazapine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): potential serotonin syndrome. - Central nervous system depressants (e.g., benzodiazepines, alcohol): enhanced sedation. - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): increased mirtazapine plasma levels.

Moderate Interactions (Monitor Closely): - Alcohol: may intensify CNS depression. - Antihistamines: additive sedative effect. - Carbamazepine or phenytoin: may reduce mirtazapine concentrations. - Fluconazole: modest increase in mirtazapine exposure.